Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
17.44
USD
|
+43.07%
|
|
+49.57%
|
+59.27%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,185
|
1,642
|
694.8
|
391.8
|
630
|
-
|
-
|
Enterprise Value (EV)
1 |
1,185
|
1,642
|
694.8
|
391.8
|
630
|
630
|
630
|
P/E ratio
|
-11.7
x
|
8.2
x
|
7.63
x
|
-3.48
x
|
-4.78
x
|
-2.8
x
|
-4.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
4.76
x
|
2.6
x
|
31.1
x
|
-
|
787
x
|
5.43
x
|
EV / Revenue
|
-
|
4.76
x
|
2.6
x
|
31.1
x
|
-
|
787
x
|
5.43
x
|
EV / EBITDA
|
-26.5
x
|
6.69
x
|
5.47
x
|
-
|
-3.21
x
|
-3.17
x
|
-
|
EV / FCF
|
-46.4
x
|
3.21
x
|
-
|
-3.67
x
|
-5
x
|
-5.21
x
|
-
|
FCF Yield
|
-2.15%
|
31.2%
|
-
|
-27.2%
|
-20%
|
-19.2%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,045
|
35,274
|
35,575
|
35,785
|
36,123
|
-
|
-
|
Reference price
2 |
33.82
|
46.56
|
19.53
|
10.95
|
17.44
|
17.44
|
17.44
|
Announcement Date
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
344.8
|
267.6
|
12.6
|
-
|
0.8
|
116.1
|
EBITDA
1 |
-
|
-44.7
|
245.5
|
127.1
|
-
|
-196
|
-199
|
-
|
EBIT
1 |
-28.05
|
-45.24
|
244.9
|
126.3
|
-151.1
|
-200.2
|
-258
|
-276.7
|
Operating Margin
|
-
|
-
|
71.03%
|
47.2%
|
-1,199.69%
|
-
|
-32,249.19%
|
-238.38%
|
Earnings before Tax (EBT)
1 |
-
|
-38.09
|
256.5
|
148.7
|
-109
|
-174.5
|
-250.3
|
-249.4
|
Net income
1 |
-22.45
|
-43.4
|
214.5
|
96.65
|
-112.6
|
-181.5
|
-264
|
-166.9
|
Net margin
|
-
|
-
|
62.22%
|
36.11%
|
-894.34%
|
-
|
-32,996.41%
|
-143.77%
|
EPS
2 |
-
|
-2.880
|
5.680
|
2.560
|
-3.150
|
-3.650
|
-6.222
|
-3.758
|
Free Cash Flow
1 |
-
|
-25.53
|
512
|
-
|
-106.7
|
-126
|
-121
|
-
|
FCF margin
|
-
|
-
|
148.49%
|
-
|
-847.34%
|
-
|
-15,125%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
208.53%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
238.65%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/22/20
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
240.5
|
152.5
|
41.72
|
19.49
|
53.9
|
12.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
213.7
|
-
|
3.53
|
-15
|
17.61
|
-24.71
|
-42.4
|
-43.06
|
-
|
-
|
-46
|
-50
|
-53
|
-
|
-
|
EBIT
1 |
213.5
|
120.8
|
3.335
|
-15.2
|
17.38
|
-24.93
|
-42.62
|
-43.28
|
-40.15
|
-47.23
|
-47.84
|
-51.48
|
-55.09
|
-64.84
|
-65.95
|
Operating Margin
|
88.78%
|
79.21%
|
7.99%
|
-78.03%
|
32.25%
|
-197.94%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
224
|
119.5
|
8.443
|
-1.986
|
22.75
|
-14.35
|
-33.07
|
-33.42
|
-28.19
|
-36
|
-41.74
|
-45.17
|
-48.91
|
-54.98
|
-56.09
|
Net income
1 |
184.9
|
69.58
|
5.626
|
0.991
|
20.45
|
-15.55
|
-34.3
|
-32.24
|
-30.55
|
-38.22
|
-41.25
|
-44.68
|
-48.42
|
-54.98
|
-56.09
|
Net margin
|
76.87%
|
45.62%
|
13.49%
|
5.09%
|
37.94%
|
-123.47%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
4.890
|
1.820
|
0.1500
|
0.0300
|
0.5500
|
-0.4400
|
-0.9600
|
-0.9000
|
-0.8500
|
-1.070
|
-0.8000
|
-0.8700
|
-0.9600
|
-1.595
|
-1.660
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/12/22
|
8/10/22
|
11/10/22
|
3/15/23
|
5/10/23
|
8/8/23
|
11/7/23
|
3/6/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-25.5
|
512
|
-
|
-107
|
-126
|
-121
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-30.2%
|
49%
|
15.9%
|
-18.2%
|
-25.9%
|
-26.2%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-23.1%
|
34.9%
|
11.8%
|
-15.8%
|
-22.6%
|
-23.1%
|
-
|
Assets
1 |
-
|
187.6
|
614.6
|
819.8
|
711.3
|
803.2
|
1,143
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
2.97
|
1
|
1
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
23.55%
|
-
|
125%
|
-
|
Announcement Date
|
5/22/20
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
17.44
USD Average target price
34.4
USD Spread / Average Target +97.25% Consensus |
1st Jan change
|
Capi.
|
---|
| +59.27% | 630M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|